



Universiteit  
Leiden  
The Netherlands

## Genetically determined serum calcium levels and markers of ventricular repolarization a Mendelian randomization study in the UK Biobank

Young, W.J.; Warren, H.R.; Mook-Kanamori, D.O.; Ramirez, J.; Duijvenboden, S. van; Orini, M.; ...  
; Noordam, R.

### Citation

Young, W. J., Warren, H. R., Mook-Kanamori, D. O., Ramirez, J., Duijvenboden, S. van, Orini, M., ... Noordam, R. (2021). Genetically determined serum calcium levels and markers of ventricular repolarization a Mendelian randomization study in the UK Biobank. *Circulation: Genomic And Precision Medicine*, 14(3), 331-338. doi:10.1161/CIRCGEN.120.003231

Version: Publisher's Version  
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)  
Downloaded from: <https://hdl.handle.net/1887/3246867>

**Note:** To cite this publication please use the final published version (if applicable).



# Genetically Determined Serum Calcium Levels and Markers of Ventricular Repolarization

## A Mendelian Randomization Study in the UK Biobank

William J. Young<sup>1</sup> ID, MBBS; Helen R. Warren<sup>2</sup> ID, PhD; Dennis O. Mook-Kanamori, MD, PhD; Julia Ramírez<sup>3</sup> ID, PhD; Stefan van Duijvenboden<sup>4</sup> ID, PhD; Michele Orini<sup>5</sup> ID, PhD; Andrew Tinker<sup>6</sup> ID, MBBS, PhD; Diana van Heemst, PhD; Pier D. Lambiase<sup>7</sup> ID, BM BCh, PhD; J. Wouter Jukema<sup>8</sup> ID, MD, PhD; Patricia B. Munroe<sup>9</sup> ID, PhD; Raymond Noordam<sup>10</sup> ID, PhD

**BACKGROUND:** ECG markers of ventricular depolarization and repolarization are associated with an increased risk of arrhythmia and sudden cardiac death. Our prior work indicated lower serum calcium concentrations are associated with longer QT and JT intervals in the general population. Here, we investigate whether serum calcium is a causal risk factor for changes in ECG measures using Mendelian randomization (MR).

**METHODS:** Independent lead variants from a newly performed genome-wide association study for serum calcium in >300 000 European-ancestry participants from UK Biobank were used as instrumental variables. Two-sample MR analyses were performed to approximate the causal effect of serum calcium on QT, JT, and QRS intervals using an inverse-weighted method in 76 226 participants not contributing to the serum calcium genome-wide association study. Sensitivity analyses including MR-Egger, weighted-median estimator, and MR pleiotropy residual sum and outlier were performed to test for the presence of horizontal pleiotropy.

**RESULTS:** Two hundred five independent lead calcium-associated variants were used as instrumental variables for MR. A decrease of 0.1 mmol/L serum calcium was associated with longer QT (3.01 ms [95% CI, 2.03 to 3.99]) and JT (2.89 ms [1.91 to 3.87]) intervals. A weak association was observed for QRS duration (secondary analyses only). Results were concordant in all sensitivity analyses.

**CONCLUSIONS:** These analyses support a causal effect of serum calcium levels on ventricular repolarization, in a middle-aged population of European-ancestry where serum calcium concentrations are likely stable and chronic. Modulation of calcium concentration may, therefore, directly influence cardiovascular disease risk.

**Key Words:** action potential ■ calcium ■ cardiovascular diseases ■ electrocardiography ■ electrolyte

**N**oninvasive markers of cardiac disease derived from the ECG are associated with major cardiovascular events and reflect underlying abnormalities in cardiac structure and electrical conduction.<sup>1–4</sup> Abnormal action potential duration and amplification of the spatial dispersion of repolarization, coupled with early after

depolarizations inducing triggered activity is an important mechanism of ventricular arrhythmia, specifically torsades de pointes tachycardia.<sup>5,6</sup> Prolongation of the QT interval, a marker of the time needed for ventricular repolarization and depolarization, has consistently been associated with adverse outcomes, including ventricular

Correspondence to: William J. Young, MBBS, Department of Clinical Pharmacology, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, United Kingdom, Email w.young@qmul.ac.uk or Raymond Noordam, PhD, Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands, Email r.noordam@lumc.nl

The Data Supplement is available at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCGEN.120.003231>.

For Sources of Funding and Disclosures, see page 336.

© 2021 The Authors. *Circulation: Genomic and Precision Medicine* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

*Circulation: Genomic and Precision Medicine* is available at [www.ahajournals.org/journal/circgen](http://www.ahajournals.org/journal/circgen)

## Nonstandard Abbreviations and Acronyms

<b>GWAS</b>	genome-wide association study
<b>MR</b>	Mendelian randomization
<b>UKB</b>	UK Biobank

arrhythmia and sudden cardiac death.<sup>7–9</sup> QRS duration (time point from QRS onset to offset) is specific for ventricular depolarization while the JT interval is specific for ventricular repolarization spanning the interval from QRS offset to T-wave end. Multiple factors may influence these ECG markers and thus the potential for arrhythmia, including mutations in genes encoding ion channels and their accessory proteins (eg, *KCNQ1* and *KCNE1*) and iatrogenic causes due to off target effects by medication (eg, cancer therapeutics and psychotropics).<sup>10–12</sup>

The different phases of the cardiac action potential are caused by the (inward and outward) movement of different ions across the membrane of the cardiac cells. Serum electrolyte concentrations are associated with alterations in ECG-derived indices of cardiac electrophysiological activity. Historically, studies have focused on the effects of electrolytes in clinical populations often with serum electrolyte concentrations significantly outside of the normal range with rapid and acute changes in their concentration.<sup>13,14</sup> We recently published the results of a large meta-analysis of cross-sectional data including 153 014 unselected individuals, investigating the association of serum electrolyte levels with ECG-derived indices.<sup>15</sup> One of the key findings was an association between lower serum calcium and longer QT (2.23 ms per 0.1 mmol/L) and JT (2.27 ms per 0.1 mmol/L) intervals but not with QRS duration. The lack of a calcium-QRS duration association suggested serum calcium specifically affects ventricular repolarization. However, given the observational and cross-sectional nature of the study, and the limited number of considered confounders, we were unable to determine whether these observations were causal.

Mendelian randomization (MR), in which genetic variants significantly associated with an exposure are used to estimate causal effects of that exposure on outcomes of interest,<sup>16–18</sup> has been widely used to assess causality in observational settings. MR overcomes the main limitations of observational studies, notably reverse causation and residual confounding.<sup>19</sup> Previous genome-wide association studies (GWAS) for serum calcium have identified associated variants and have been leveraged before in MR studies for cardiovascular disease risk.<sup>20–23</sup> However, due to the relatively small sample sizes of these GWAS which limited the number of associations identified, the genetic instruments included in MR analyses explained only a small proportion of the variance of calcium ( $\approx 0.9\%$ ).<sup>24,25</sup> The release of biochemical data in UK Biobank (UKB) permits the identification

of additional genetic variants for serum calcium in larger samples increasing the number of variants and consequently increasing the power of an MR study.<sup>26,27</sup> In this study, we performed a new GWAS on serum total calcium and used the independent lead variants as instrumental variables to assess potential causality of the association between lower serum calcium and prolongation of QT and JT intervals in UKB, including QRS duration as a negative control.

## METHODS

Anonymized clinical, genotype, and ECG data were obtained from UKB.<sup>27</sup> The UKB study has approval from the National Health Service North West Multi-Centre Research Ethics Committee (ref 11/NW/0382) and participating studies provided informed consent. Any data generated by this study will be returned to UKB in accordance with researcher obligations, to be made available for further research. Full methods are available in Methods in the [Data Supplement](#) and also summarized in Figure 1.

## RESULTS


### Calcium GWAS

We identified 208 independent lead variants (201 from novel loci) associated with serum total calcium concentration at genome-wide significance level ( $P < 5 \times 10^{-8}$ ; Table I in the [Data Supplement](#)). A Manhattan plot and quantile-quantile plot are shown in Figures I and II in the [Data Supplement](#). The percentage variance of total serum calcium explained by variants included in this MR study was 5.8% (compared with 0.9% for previously reported variants).<sup>24</sup> Previously reported variants associated with serum calcium showed the same direction of effect and similar effect size estimates (Table II in the [Data Supplement](#)). There were 208 independent lead genome-wide significant variants identified in the albumin-corrected calcium GWAS, of which 151 were in loci overlapping with those reported in the uncorrected calcium GWAS at  $P < 5 \times 10^{-8}$  (Figure III in the [Data Supplement](#)). The correlation between results of genome-wide significant loci between the original versus the albumin-corrected GWAS was  $r^2 = 0.88$  for the  $\beta$  estimates and  $r^2 = 0.55$  for the  $P$  values (Spearman rank coefficient). Following exclusion of palindromic single-nucleotide polymorphisms with intermediate allele frequencies, 205 and 202 variants for total serum calcium and albumin-corrected calcium respectively, were included in MR analyses.

## MENDELIAN RANDOMIZATION ANALYSES

### Primary Analysis—Inverse-Variance Weighted

Study characteristics for individuals included in each ECG cohort-specific GWAS and subsequently combined



**Figure 1. Workflow indicating the methods for GWAS of serum calcium and ECG traits.**

\*Phenotypic exclusions included a prior diagnosis of myocardial infarction or heart failure, QRS duration >120 ms or right/left bundle branch block on ECG, pacemaker in-situ, currently pregnant, or taking digitalis medication, class I/III antiarrhythmics or specific QT prolongation medication. †Indicators of poor genotype quality included high heterozygosity/missingness/sex mismatch. Array: indicator for UK Biobank (UKBB) or UK BiLEVE (UKBL) array to adjust for genotyping chip. GWAS indicates genome-wide association study; GWS, genome-wide significant ( $P < 5 \times 10^{-8}$ ); INFO, imputation quality score; MAF, minor allele frequency; MR, Mendelian randomization; and SNP, single nucleotide polymorphism.

in the meta-analysis, and the calcium GWAS are shown in Table 1. A total of 76 266 participants were included with a median age of 61 (interquartile range: 54–66) years and 53.1% were women.

The results for the estimated causal effect of total serum calcium on the ECG measures are shown in Table 2. Using the inverse-variance weighted model, a genetically determined 0.1 mmol/L decrease in serum total calcium was associated with a 3.01 ms (95% CI, 2.03 to 3.99) longer QT interval and a 2.89 ms (1.91 to 3.87) longer JT interval. No association was found with QRS duration (0.20 ms [−0.10 to 0.49]). The results for albumin-corrected calcium were similar showing the strongest association with QT and JT intervals, but a weak association with QRS duration was observed (0.39 ms [0.08 to 0.69] Table III in the [Data Supplement](#)).

### Sensitivity Analyses

Genetically determined lower serum calcium concentrations were consistently associated with longer QT and JT intervals across sensitivity analyses using

weighted-median estimator, MR-Egger and Mendelian randomization pleiotropy residual sum and outlier methods, with similar or stronger effect sizes as using the inverse-variance weighted model (Table 2 and Table III in the [Data Supplement](#)). Furthermore, we did not observe that any of the intercepts with MR-Egger deviated significantly from zero ( $P > 0.05$ ), indicating no evidence of bias from pleiotropy. The results were similar after exclusion of instrumental variants using a more stringent  $r^2$  threshold ( $> 0.001$ ), (Table IV in the [Data Supplement](#)).

Similar results were identified after exclusion of the variant mapped to *CASR*, a locus, which is a major genetic determinant of serum calcium concentration.<sup>21</sup> Scatter plots for serum total calcium analyses are presented in Figure 2A through 2C for each ECG measure. Funnel plots did not indicate any directional horizontal pleiotropy (Figure IVA through IVC in the [Data Supplement](#)).

### DISCUSSION

This study uses MR to demonstrate the causal inverse relationship between serum calcium concentration and longer

**Table 1. Study Characteristics for Each ECG Cohort and Combined**

	Calcium GWAS cohort	ECG cohorts		
		IMAGING-UKB	EST-UKB	Combined
No. of individuals	305 349	29 683	46 543	76 226
Sex (female)	53.0%	52.7%	53.3%	53.1%
Age, y	58 (50–63)	64 (58–69)	59 (51–64)	61 (54–66)
BMI	26.7 (24.1–29.9)	25.3 (22.9–28.1)	26.4 (24.0–29.4)	26.0 (23.5–28.9)
Height, cm	168 (162–176)	170 (163–177)	169 (162–176)	169 (163–176)
Systolic BP, mmHg	136.5 (124.5–149.5)	133.5 (122.5–146.0)	135.5 (124.0–148.0)	135.0 (123.5–147.5)
Diastolic BP, mmHg	82.0 (75.0–89.0)	81.0 (74.5–88.0)	81.5 (75.0–88.0)	81.5 (75.0–88.0)
Pulse rate, bpm	68.5 (61.5–76)	67 (60.5–74.0)	67 (61–74)	67 (60.5–74.0)
Calcium, mmol/L	2.37 (2.32–2.43)	2.37 (2.32–2.43)	2.39 (2.33–2.45)	2.38 (2.32–2.44)
Corrected calcium, mmol/L	2.27 (2.22–2.32)	2.26 (2.22–2.31)	2.27 (2.22–2.32)	2.27 (2.22–2.32)
*RR interval, ms	...	985 (885–1091)	852 (764–947)	900 (799–1013)
*QT, ms	...	398 (378–419)	356.5 (340–374)	370.5 (349–396)
*JT, ms	...	313 (294–335)	270 (253.5–287)	284 (263–311)
*QRS, ms	...	84 (77–91)	86 (83–91)	85 (81–91)

Continuous variables are reported as median (interquartile range). BMI indicates body mass index; BP, blood pressure; EST-UKB, exercise stress test cohort; GWAS, genome-wide association study; and IMAGING-UKB, imaging study cohort.

\*Measures derived from ECG analysis.

QT and JT intervals in UKB, a large middle-aged European ancestry population. This inverse relationship was consistent across all sensitivity analyses. These results along with the absence of a clinically relevant association with QRS duration due to its very small effect size, collectively suggest that a genetically predicted lower serum calcium is a causal contributor primarily for increasing ventricular repolarization time in a population where serum calcium concentration exposure is likely stable and chronic. They also highlight the utility of MR in the investigation of clinically relevant variables and their contribution, to specific time points in ventricular cardiac electrophysiology.

It is well recognized that extremes of both hypocalcemia and hypercalcemia in clinical cohorts result in prolongation and shortening of ventricular repolarization, respectively.<sup>28</sup> However, there has previously been limited study of the influence of stable calcium concentrations in population-based studies. We previously reported an inverse association between serum total calcium concentration and QT and JT intervals in a large


meta-analysis of observational studies with over 150 K unselected individuals.<sup>15</sup> Specifically, we observed a 2.23 ms longer QT interval and 2.27 ms longer JT interval per 0.1 mmol/L decrease in serum calcium, in the absence of a limited number of considered confounding factors.<sup>15</sup> These effect size estimates are similar to those obtained in this MR study, using individuals from UKB. It should be noted that UKB was not included in our previous observational meta-analysis study and is thus an independent cohort. When comparing the MR results of serum uncorrected calcium with the secondary analysis using albumin-corrected calcium, our findings were very similar with strong associations identified with QT and JT intervals. The marginal association between serum albumin-corrected calcium and QRS duration was considered not clinically relevant and anticipated given some overlap exists between the genetic contributions of QRS and QT/JT intervals.<sup>29</sup>

Previous randomized control and crossover trials estimated an increase in serum total calcium of 0.07

**Table 2. Association Between Serum Total Calcium Concentration and Measures of Ventricular Depolarization and Repolarization Using Mendelian Randomization**

	No. of SNPs	Inverse-median weighted		Median-weighted		MR-Egger		MR-PRESSO outlier adjusted	
		$\beta$ (95% CI)	<i>P</i> value	$\beta$ (95% CI)	<i>P</i> value	$\beta$ (95% CI)	<i>P</i> value	$\beta$ (95% CI)	<i>P</i> value
QT interval	205	-3.01 (-3.99 to -2.03)	$1.10 \times 10^{-9}$	-4.02 (-5.04 to -3.00)	$1.59 \times 10^{-14}$	-4.61 (-6.43 to -2.79)	$1.52 \times 10^{-6}$	-3.24 (-3.98 to -2.50)	$1.23 \times 10^{-14}$
JT interval	205	-2.89 (-3.87 to -1.91)	$4.36 \times 10^{-9}$	-4.24 (-5.28 to -3.20)	$9.40 \times 10^{-16}$	-4.51 (-6.31 to -2.71)	$2.09 \times 10^{-6}$	-3.2 (-4.00 to -2.40)	$3.69 \times 10^{-13}$
QRS duration	205	-0.2 (-0.49 to 0.10)	0.18	-0.44 (-0.93 to 0.05)	0.08	-0.13 (-0.70 to 0.44)	0.65	-0.14 (-0.41 to 0.13)	0.32

$\beta$  indicates effect size (ms change per 0.1 mmol/L). MR-PRESSO indicates Mendelian randomization pleiotropy residual sum and outlier; and SNP, single-nucleotide polymorphism.



**Figure 2. Scatter plot for Mendelian randomization (MR) serum total calcium analyses for QT, JT and QRS.**

Scatter plots of individual variant regression coefficients with inverse-variance weighted, weighted-median, and MR-Egger slope estimates. A, QT. B, JT. C, QRS. SNP indicates single nucleotide polymorphism.

to 0.13 mmol/L  $\approx$ 4 hours after ingestion of calcium carbonate (500 mg).<sup>30,31</sup> Thus, the results of this study suggest oral calcium supplementation could temporarily decrease the QT interval by 2.11 to 3.91 ms. As the effect of oral calcium supplementation on serum total calcium concentration is small, we would expect no direct clinical benefits. However, the results of this study suggest further research into the effects of serum calcium concentration on arrhythmogenesis is warranted and calcium variants could be considered for inclusion in genetic risk score models for risk prediction. This may

be of particular importance in patient sub-groups such as endocrinology disorders affecting calcium homeostasis, concurrent use of medication which prolong the QT interval, and in the context of other comorbidities where a substrate exists for ventricular arrhythmia such as ischemic heart disease, cardiomyopathies, or channelopathies.<sup>12,32</sup>

Although an inverse relationship between calcium and markers of ventricular repolarization were identified in this study, associations between higher serum calcium concentrations and increased cardiovascular

disease risk including myocardial infarction, stroke, and cardiovascular mortality have been reported in individual epidemiological studies, meta-analyses, and some randomized control trials.<sup>33–35</sup> These observations are present at serum calcium concentrations within the normal reference range (association at high-normal concentrations). Thus, there is interest in the use of serum calcium levels in the assessment of cardiovascular risk. To date, 6 MR studies have been performed evaluating the effect of calcium on cardiovascular outcomes using 7 independent variants identified from a previous serum calcium meta-analysis (N≈61 000).<sup>24</sup> Despite the small percentage variance of calcium explained by these variants (≈0.9%), a significant association was identified between serum calcium and coronary artery disease and myocardial infarction, a finding recently replicated in a Mendelian randomization - phenome-wide association study performed in UKB (odds ratio, 1.99 for myocardial infarction per 0.25 mmol/L increase in genetically predicted serum calcium [CI, 1.17–3.39]).<sup>20,36,37</sup> For atrial fibrillation, an MR study identified no significant association in the main analyses.<sup>21</sup> However, directional pleiotropy was identified and in MR-Egger analyses, an association was observed (odds ratio, 1.30 per 0.25 mmol/L increase [CI, 1.05–1.59]) driven by a single variant in the *CASR* locus. This variant out of those included as instrumental variables, explained 0.5% of the variance of serum calcium. Significant associations have not been observed with heart failure (as an end point after myocardial infarction) or stroke risk.<sup>22,23</sup> Additionally, despite calcium supplementation being common in the general population with the intention to reduce the risk of fractures, an association between life-long calcium levels and risk of fracture was not observed in a previous MR study.<sup>38</sup> However, these studies may have been limited by the low variation of calcium explained by variants included in the MR analyses, despite having large sample sizes for testing these clinical outcomes.<sup>39</sup>

Despite showing evidence for a causal association between lower serum calcium and longer QT and JT intervals, this study does not provide information on the biological mechanisms involved, which remain uncertain. In animal models, the duration of phase II of the cardiac action potential is determined by the inactivation of voltage-gated long-lasting calcium channels, which are dependent on calcium entering these channels and their release from the sarcoplasmic reticulum.<sup>28,40</sup> Higher extracellular calcium concentrations increase long-lasting calcium channel inactivation which in turn reduces phase II of the action potential and the inverse is present in lower calcium concentration states, as identified in a more recent in-silico theoretical study using a human ventricular myocyte model.<sup>41</sup> These mechanisms could explain the associations observed in our study between serum calcium and ventricular repolarization.

## Strengths and Limitations

The present study performed a new serum calcium GWAS to increase the number of genetic instrumental variables and to increase the variance explained to perform a more statistically powerful MR analysis. Furthermore, 2-sample MR studies assume the 2 samples (exposure and outcome) were performed in different individuals from the same source population. By design, we performed the new calcium GWAS in individuals not contributing to the QT/JT/QRS intervals GWASs ensuring this assumption was met.

UKB is a densely phenotyped cohort, and participants are generally healthy compared with the general UK population. Additionally, this study was conducted only in individuals of European ancestry due to a limited sample size available for other ancestries. Therefore, these results may not be extrapolated to population groups of non-European ancestry or within high-risk clinical cohorts such as postmyocardial infarction or channelopathies showing a mendelian pattern of inheritance.

## Conclusions

In summary, this MR study indicates that genetically determined lower serum calcium concentrations are causally associated with longer ventricular repolarization time in a middle-aged population where serum calcium concentration exposure is likely stable and chronic. Modulation of calcium concentration may, therefore, directly influence cardiovascular disease risk. Additionally, we have shown that the power of MR studies can be harnessed to improve our understanding of cardiac electrophysiology, and a similar approach could be considered using other clinically relevant exposures.

## ARTICLE INFORMATION

Received October 12, 2020; accepted April 2, 2021.

### Affiliations

Clinical Pharmacology Department, William Harvey Research Institute (W.J.Y., H.R.W., J.R., S.v.D., A.T., P.B.M.) and NIHR Barts Cardiovascular Biomedical Research Unit (H.R.W., A.T., P.B.M.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS trust (W.J.Y., M.O., P.D.L.). Department of Clinical Epidemiology (D.O.M.-K.), Department of Public Health and Primary Care (D.O.M.-K.), Department of Internal Medicine (D.v.H., R.N.), Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands. Institute of Cardiovascular Sciences, University of College London, United Kingdom (J.R., S.v.D., M.O., P.D.L.). Netherlands Heart Institute, Utrecht, the Netherlands (J.W.J.).

### Acknowledgments

This research has been conducted using the UK Biobank Resource (application 8256—Understanding genetic influences in the response of the cardiac electrical system to exercise).

### Sources of Funding

Dr W.J. Young is supported by a Medical Research Council (MRC) grant MR/R017468/1. This research has been conducted using the UK Biobank Resource (application 8256—Understanding genetic influences in the response of the cardiac electrical system to exercise) and is supported by MRC grant MR/N025083/1. Dr W.J. Young, Dr Warren, Dr Ramírez, Professor Tinker, Professor

Lambiase, and Professor Munroe acknowledge the National Institute for Health Research (NIHR) Cardiovascular Biomedical Centre at Barts and The London, Queen Mary University of London. Professor Lambiase is supported by University College London/University College London Hospitals NHS Foundation trust UCL/UCLH Biomedicine NIHR, Barts Heart Centre Biomedical Research Centre. Dr Ramírez acknowledges support from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No.786833.

## Disclosures

Dr Mook-Kanamori is a part time research consultant at Metabolon, Inc. The other authors report no conflicts.

## Supplemental Materials

Supplemental Methods  
Supplemental Tables I–IV  
Supplemental Figures I–IV  
References<sup>51–57</sup>

## REFERENCES

- Hayroğlu Mİ, Lakhani I, Tse G, Çınar T, Çinier G, Tekkeşin AI. In-hospital prognostic value of electrocardiographic parameters other than ST-segment changes in acute myocardial infarction: literature review and future perspectives. *Heart Lung Circ.* 2020;29:1603–1612. doi: 10.1016/j.hlc.2020.04.011
- Enriquez A, Riley M, Marchlinski F. Noninvasive clues for diagnosing ventricular tachycardia mechanism. *J Electrocardiol.* 2018;51:163–169. doi: 10.1016/j.jelectrocard.2017.11.009
- Holkeri A, Eranti A, Haukilahti MAE, Kerola T, Kenttå TV, Tikkanen JT, Anttonen O, Noponen K, Seppänen T, Rissanen H, et al. Predicting sudden cardiac death in a general population using an electrocardiographic risk score. *Heart.* 2020;106:427–433. doi: 10.1136/heartjnl-2019-315437
- Kristensen SL, Castagno D, Shen L, Jhund PS, Docherty KF, Rørth R, Abraham WT, Desai AS, Dickstein K, Rouleau JL, et al; PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. *Eur J Heart Fail.* 2020;22:2370–2379. doi: 10.1002/ejhf.1972
- Antzelevitch C. Cardiac repolarization. The long and short of it. *Eurpace.* 2005;7(suppl 2):3–9. doi: 10.1016/j.eupc.2005.05.010
- Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. *Mayo Clin Proc.* 2009;84:289–297. doi: 10.1016/S0025-6196(11)61149-X
- Straus SM, Kors G, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. *J Am Coll Cardiol.* 2006;47:362–367. doi: 10.1016/j.jacc.2005.08.067
- Beinart R, Zhang Y, Lima JA, Bluemke DA, Soliman EZ, Heckbert SR, Post WS, Guallar E, Nazarian S. The QT interval is associated with incident cardiovascular events: the MESA study. *J Am Coll Cardiol.* 2014;64:2111–2119. doi: 10.1016/j.jacc.2014.08.039
- Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. *Circulation.* 1978;57:1074–1077. doi: 10.1161/01.cir.57.6.1074
- Bohnen MS, Peng G, Robey SH, Terrenoire C, Iyer V, Sampson KJ, Kass RS. Molecular pathophysiology of congenital long QT syndrome. *Physiol Rev.* 2017;97:89–134. doi: 10.1152/physrev.00008.2016
- Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavandiranathan P. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. *J Am Heart Assoc.* 2017;6:e007724.
- Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. *Psychosomatics.* 2018;59:105–122. doi: 10.1016/j.psym.2017.10.009
- Ahmed R, Kiya F, Kitano K, Takagi H, Hashiba K. Effects of combined changes in serum calcium and potassium on QT interval. A study by Holter electrocardiographic monitoring during hemodialysis. *Jpn Heart J.* 1987;28:813–828. doi: 10.1536/ihj.28.813
- Surawicz B. Relationship between electrocardiogram and electrolytes. *Am Heart J.* 1967;73:814–834. doi: 10.1016/0002-8703(67)90233-5
- Noordam R, Young WJ, Salman R, Kanter JK, van den Berg ME, van Heemst D, Lin HJ, Barreto SM, Biggs ML, Biino G, et al. Effects of calcium, magnesium, and potassium concentrations on ventricular repolarization in unselected individuals. *J Am Coll Cardiol.* 2019;73:3118–3131. doi: 10.1016/j.jacc.2019.03.519
- Lawlor DA. Commentary: two-sample Mendelian randomization: opportunities and challenges. *Int J Epidemiol.* 2016;45:908–915. doi: 10.1093/ije/dyw127
- Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med.* 2008;27:1133–1163. doi: 10.1002/sim.3034
- Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across the human genome. *Elife.* 2018;7:e34408.
- Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. *JAMA.* 2017;318:1925–1926. doi: 10.1001/jama.2017.17219
- Xu L, Lin SL, Schooling CM. A Mendelian randomization study of the effect of calcium on coronary artery disease, myocardial infarction and their risk factors. *Sci Rep.* 2017;7:42691. doi: 10.1038/srep42691
- Larsson SC, Drca N, Michaëlsson K. Serum magnesium and calcium levels and risk of atrial fibrillation. *Circ Genom Precis Med.* 2019;12:e002349. doi: 10.1161/CIRCGEN.118.002349
- Larsson SC, Traylor M, Burgess S, Boncoraglio GB, Jern C, Michaëlsson K, Markus HS; MEGASTROKE Project of the International Stroke Genetics Consortium. Serum magnesium and calcium levels in relation to ischemic stroke: Mendelian randomization study. *Neurology.* 2019;92:e944–e950. doi: 10.1212/WNL.00000000000007001
- Helte E, Åkesson A, Larsson SC. Assessing causality in associations of serum calcium and magnesium levels with heart failure: a two-sample Mendelian randomization study. *Front Genet.* 2019;10:1069. doi: 10.3389/fgene.2019.01069
- O'Seaghda CM, Wu H, Yang Q, Kapur K, Guessous I, Zuber AM, Kötting A, Stoudmann C, Teumer A, Kutalik Z, et al; SUNLIGHT Consortium; GEFOS Consortium. Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrations. *PLoS Genet.* 2013;9:e1003796. doi: 10.1371/journal.pgen.1003796
- O'Seaghda CM, Yang Q, Glazer NL, Leak TS, Dehghan A, Smith AV, Kao WH, Lohman K, Hwang SJ, Johnson AD, et al; GEFOS Consortium. Common variants in the calcium-sensing receptor gene are associated with total serum calcium levels. *Hum Mol Genet.* 2010;19:4296–4303. doi: 10.1093/hmg/ddq342
- Biobank U. Serum Biochemistry Manual. Accessed September 13, 2020. <https://www.ukbiobank.ac.uk/uk-biobank-biomarker-panel/>
- Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature.* 2018;562:203–209. doi: 10.1038/s41586-018-0579-z
- Kass RS, Tsien RW. Control of action potential duration by calcium ions in cardiac Purkinje fibers. *J Gen Physiol.* 1976;67:599–617. doi: 10.1085/jgp.67.5.599
- Sotoodehnia N, Isaacs A, de Bakker PI, Dörr M, Newton-Cheh C, Nolte IM, van der Harst P, Müller M, Eijgelsheim M, Alonso A, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. *Nat Genet.* 2010;42:1068–1076. doi: 10.1038/ng.716
- Heaney RP, Dowell MS, Bierman J, Hale CA, Bendich A. Absorbability and cost effectiveness in calcium supplementation. *J Am Coll Nutr.* 2001;20:239–246. doi: 10.1080/07315724.2001.10719038
- Bristow SM, Gamble GD, Stewart A, Kalluru R, Horne AM, Reid IR. Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial. *Br J Nutr.* 2015;113:1585–1594. doi: 10.1017/S000711451500080X
- Brown SJ, Ruppe MD, Tabatabai LS. The parathyroid gland and heart disease. *Methodist Debakey Cardiovasc J.* 2017;13:49–54. doi: 10.14797/mdcj-13-2-49
- Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. *BMJ.* 2011;342:d2040. doi: 10.1136/bmj.d2040
- Rohrmann S, Garmo H, Malmström H, Hammar N, Jungner I, Walldius G, Van Hemelrijck M. Association between serum calcium concentration and risk of incident and fatal cardiovascular disease in the

- prospective AMORIS study. *Atherosclerosis*. 2016;251:85–93. doi: 10.1016/j.atherosclerosis.2016.06.004
35. Reid IR, Gamble GD, Bolland MJ. Circulating calcium concentrations, vascular disease and mortality: a systematic review. *J Intern Med*. 2016;279:524–540. doi: 10.1111/joim.12464
  36. Zhou A, Morris HA, Hyppönen E. Health effects associated with serum calcium concentrations: evidence from MR-PheWAS analysis in UK Biobank. *Osteoporos Int*. 2019;30:2343–2348. doi: 10.1007/s00198-019-05118-z
  37. Larsson SC, Burgess S, Michaëlsson K. Association of genetic variants related to serum calcium levels with coronary artery disease and myocardial infarction. *JAMA*. 2017;318:371–380. doi: 10.1001/jama.2017.8981
  38. Cerani A, Zhou S, Forgetta V, Morris JA, Trajanoska K, Rivadeneira F, Larsson SC, Michaëlsson K, Richards JB. Genetic predisposition to increased serum calcium, bone mineral density, and fracture risk in individuals with normal calcium levels: Mendelian randomisation study. *BMJ*. 2019;366:l4410. doi: 10.1136/bmj.l4410
  39. von Hinke Kessler Scholder S, Smith GD, Lawlor DA, Propper C, Windmeijer F. Mendelian randomization: the use of genes in instrumental variable analyses. *Health Econ*. 2011;20:893–896. doi: 10.1002/hec.1746
  40. Linz KW, Meyer R. Control of L-type calcium current during the action potential of guinea-pig ventricular myocytes. *J Physiol*. 1998;513 (pt 2):425–442. doi: 10.1111/j.1469-7793.1998.425bb.x
  41. Grandi E, Pasqualini FS, Pes C, Corsi C, Zaza A, Severi S. Theoretical investigation of action potential duration dependence on extracellular Ca<sup>2+</sup> in human cardiomyocytes. *J Mol Cell Cardiol*. 2009;46:332–342. doi: 10.1016/j.yjmcc.2008.12.002
  42. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjálmsson BJ, Finucane HK, Salem RM, Chasman DI, Ridker PM, Neale BM, Berger B, et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet*. 2015;47:284–290. doi: 10.1038/ng.3190
  43. Correcting the calcium. *Br Med J*. 1977;1:598.
  44. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. *Br Med J*. 1973;4:643–646. doi: 10.1136/bmj.4.5893.643
  45. Winkler TW, Day FR, Croteau-Chonka DC, Wood AR, Locke AE, Mägi R, Ferreira T, Fall T, Graff M, Justice AE, et al; Genetic Investigation of Anthropometric Traits (GIANT) Consortium. Quality control and conduct of genome-wide association meta-analyses. *Nat Protoc*. 2014;9:1192–1212. doi: 10.1038/nprot.2014.071
  46. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM; Schizophrenia Working Group of the Psychiatric Genomics Consortium. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47:291–295. doi: 10.1038/ng.3211
  47. The Math Works, Inc. MATLAB. Version 2018b, The Math Works, Inc., 2018. Computer Software. <https://uk.mathworks.com/products/matlab.html>.
  48. Orini M, Graham AJ, Martínez-Naharro A, Andrews CM, de Marvao A, Statton B, Cook SA, O'Regan DP, Hawkins PN, Rudy Y, et al. Noninvasive mapping of the electrophysiological substrate in cardiac amyloidosis and its relationship to structural abnormalities. *J Am Heart Assoc*. 2019;8:e012097. doi: 10.1161/JAHA.119.012097
  49. Manriquez AI, Zhang Q. An algorithm for QRS onset and offset detection in single lead electrocardiogram records. *Annu Int Conf IEEE Eng Med Biol Soc*. 2007;2007:541–544. doi: 10.1109/IEMBS.2007.4352347
  50. Bihlmeyer NA, Brody JA, Smith AV, Warren HR, Lin H, Isaacs A, Liu CT, Marten J, Radmanesh F, Hall LM, et al. ExomeChip-wide analysis of 95 626 individuals identifies 10 novel loci associated with QT and JT intervals. *Circ Genom Precis Med*. 2018;11:e001758. doi: 10.1161/CIRCGEN.117.001758
  51. van Setten J, Verweij N, Mbarek H, Niemeijer MN, Trompet S, Arking DE, Brody JA, Gandin I, Grarup N, Hall LM, et al. Genome-wide association meta-analysis of 30,000 samples identifies seven novel loci for quantitative ECG traits. *Eur J Hum Genet*. 2019;27:952–962. doi: 10.1038/s41431-018-0295-z
  52. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26:2190–2191. doi: 10.1093/bioinformatics/btq340
  53. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81:559–575. doi: 10.1086/519795
  54. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med*. 2017;36:1783–1802. doi: 10.1002/sim.7221
  55. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44:512–525. doi: 10.1093/ije/dyv080
  56. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol*. 2016;40:304–314. doi: 10.1002/gepi.21965
  57. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet*. 2018;50:693–698. doi: 10.1038/s41588-018-0099-7